Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 nov. 2025 07h54 HE | Source: SNS Insider pvt ltd

Anti-Obesity Drugs Market Size to Reach $35.52 Billion by 2032, Driven by Advancements in Weight Management Therapies and Rising Obesity Prevalence | SNS Insider

Austin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Anti-Obesity Drugs Market Size & Growth Analysis: According to SNS Insider, the Anti-Obesity Drugs Market size was valued at $5.75 billion in 2024 and...
10 nov. 2025 10h25 HE | Source: ACTG

ACTG Presents SLIM LIVER Findings at AASLD Liver Meeting Demonstrating Improvements in Biomarkers of Cardiovascular Risk among People Living with HIV and MASLD Who Receive Semaglutide

Treating people living with HIV and metabolic dysfunction-associated MASLD with semaglutide significantly improved biomarkers of cardiovascular risk.
04 nov. 2025 19h22 HE | Source: XMD Wellness

RPX Enterprises and Xyngular Introduce XMD Wellness, a New Approach to Weight Loss and Wellness

New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness accessible nationwide.
30 oct. 2025 08h00 HE | Source: Rani Therapeutics, LLC

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
30 oct. 2025 08h00 HE | Source: Biomea Fusion, Inc.

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present...
07 oct. 2025 05h00 HE | Source: Resalis Therapeutics SRL

Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings

Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class...
27 juil. 2025 16h23 HE | Source: The Rosen Law Firm PA

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS

NEW YORK, July 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April...
23 juin 2025 10h46 HE | Source: Block & Leviton LLP

BREAKING: Hims & Hers Health, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Block & Leviton is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. Investors should contact the firm.
27 mai 2025 12h39 HE | Source: Sagapixel

Sagapixel: GLP-1 Surpasses Ozempic in Search Volume, Signaling a New Era in Patient Awareness and Provider Strategy

Sagapixel reports “GLP-1” has overtaken “Ozempic” in search volume, signaling a major shift in patient awareness and provider marketing and SEO strategy.
22 mai 2025 08h16 HE | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re

Page suivante